Search

Your search keyword '"Grova, M."' showing total 13 results
Start Over Author "Grova, M." Publisher elsevier bv
13 results on '"Grova, M."'

1. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE

Author

Macaluso, F.S., primary, Grova, M., additional, Mocciaro, F., additional, Di Mitri, R., additional, Privitera, A., additional, Distefano, M., additional, Vitello, A., additional, Camilleri, S., additional, Ferracane, C., additional, Pluchino, D., additional, Belluardo, N., additional, Giangreco, E., additional, Fries, W., additional, Viola, A., additional, Cappello, M., additional, D'Amato, L., additional, Bertolami, C., additional, Ventimiglia, M., additional, Renna, S., additional, Casa, A., additional, De Vivo, S., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

2. T.10.1 SAFETY AND EFFECTIVENESS OF TOFACITINIB IN ULCERATIVE COLITIS: REAL-WORLD DATA FROM TOFA-UC, A SN-IBD STUDY

Author

Macaluso, F.S., primary, D'Antonio, E., additional, Fries, W., additional, Viola, A., additional, Ksissa, O., additional, Cappello, M., additional, Muscarella, S., additional, Belluardo, N., additional, Giangreco, E., additional, Mocciaro, F., additional, Di Mitri, R., additional, Ferracane, C., additional, Vitello, A., additional, Grova, M., additional, Renna, S., additional, Casa, A., additional, Ventimiglia, M., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

3. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS

Author

Onali, S., primary, Pugliese, D., additional, Caprioli, F.A., additional, Orlando, A., additional, Biancone, L., additional, Nardone, O.M., additional, Imperatore, N., additional, Fiorino, G., additional, Cappello, M., additional, Viola, A., additional, Principi, M.B., additional, Bezzio, C., additional, Aratari, A., additional, Carparelli, S., additional, Mancuso, F., additional, Grossi, L., additional, Bodini, G., additional, Ribaldone, D., additional, Mocci, G., additional, Favale, A., additional, Grova, M., additional, Scucchi, L., additional, Segato, S., additional, Fries, W., additional, Castiglione, F., additional, Armuzzi, A., additional, and Fantini, M.C., additional

Published
2022
Full Text
View/download PDF

4. OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN’S DISEASE

Author

Macaluso, F.S., primary, Grova, M., additional, Saladino, M., additional, Demarzo, M.G., additional, Privitera, A.C., additional, Giangreco, E., additional, Garufi, S., additional, Renna, S., additional, Casà, A., additional, Ventimiglia, M., additional, Cappello, M., additional, Fries, W., additional, and Orlando, A., additional

Published
2022
Full Text
View/download PDF

5. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Author

Salomone, F., primary, Cacciola, I., additional, Petta, S., additional, Calvaruso, V., additional, Micek, A., additional, Madonia, S., additional, Grova, M., additional, Distefano, M., additional, Cannavò, M., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Di Lorenzo, F., additional, Bertino, G., additional, Licata, A., additional, Latteri, F., additional, Benanti, F., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Iacobello, C., additional, Montineri, A., additional, Colletti, P., additional, Cartabellotta, F., additional, Davì, A., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2022
Full Text
View/download PDF

6. Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model

Author

Celsa, C., primary, Cabibbo, G., additional, Battaglia, S., additional, Giuffrida, P., additional, Rizzo, G.E.M., additional, Grova, M., additional, Giacchetto, C.M., additional, Rancatore, G., additional, Stornello, C., additional, Grassini, M.V., additional, Badalamenti, G., additional, Enea, M., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2022
Full Text
View/download PDF

8. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

Author

Macaluso, F.S., primary, Cappello, M., additional, Crispino, F., additional, Grova, M., additional, Privitera, A.C., additional, Piccillo, G., additional, Magnano, A., additional, Ferracane, C., additional, Belluardo, N., additional, Giangreco, E., additional, Fries, W., additional, Viola, A., additional, Di Mitri, R., additional, Mocciaro, F., additional, Camilleri, S., additional, Garufi, S., additional, Renna, S., additional, Casà, A., additional, Maida, M., additional, and Orlando, A., additional

Published
2021
Full Text
View/download PDF

9. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2

Author

Macaluso, F.S., primary, Fries, W., additional, Viola, A., additional, Centritto, A., additional, Cappello, M., additional, Giuffrida, E., additional, Privitera, A.C., additional, Piccillo, G., additional, Magnano, A., additional, Vinci, E., additional, Vassallo, R., additional, Trovatello, A., additional, Belluardo, N., additional, Giangreco, E., additional, Camilleri, S., additional, Garufi, S., additional, Bertolami, C., additional, Ventimiglia, M., additional, Renna, S., additional, Orlando, R., additional, Rizzuto, G., additional, Grova, M., additional, and Orlando, A., additional

Published
2020
Full Text
View/download PDF

12. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

Author

Benedetta Stefanini, Laura Bucci, Valentina Santi, Nicola Reggidori, Davide Rampoldi, Lorenzo Lani, Alessandro Granito, Angelo Sangiovanni, Giuseppe Cabibbo, Fabio Farinati, Claudia Campani, Francesco Giuseppe Foschi, Gianluca Svegliati-Baroni, Giovanni Raimondo, Antonio Gasbarrini, Andrea Mega, Elisabetta Biasini, Rodolfo Sacco, Filomena Morisco, Eugenio Caturelli, Gianpaolo Vidili, Francesco Azzaroli, Edoardo G. Giannini, Gian Ludovico Rapaccini, Maurizia Rossana Brunetto, Alberto Masotto, Gerardo Nardone, Mariella Di Marco, Donatella Magalotti, Franco Trevisani, Maurizio Biselli, Paolo Caraceni, Annagiulia Gramenzi, Francesco Tovoli, Luca Muratori, Francesca Benevento, Gloria Allegrini, Calogero Cammà, Ciro Celsa, Paolo Giuffrida, Caterina Stornello, Mauro Grova, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Valentina Adotti, Stefano Gitto, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Anna Chiara Dall'Aglio, Giorgio Ercolani, Federica Mirici, Nicoletta de Matthaeis, Francesca Romana Ponziani, Gabriele Missale, Andrea Olivani, Maria Guarino, Valentina Cossiga, Mario Capasso, Ester Marina Cela, Antonio Facciorusso, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Serena Dell'Isola, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Giulia Pieri, Maria Corina Plaz Torres, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, null Matteo Renzulli, Stefanini, B., Bucci, L., Santi, V., Reggidori, N., Rampoldi, D., Lani, L., Granito, A., Sangiovanni, A., Cabibbo, G., Farinati, F., Campani, C., Foschi, F. G., Svegliati-Baroni, G., Raimondo, G., Gasbarrini, A., Mega, A., Biasini, E., Sacco, R., Morisco, F., Caturelli, E., Vidili, G., Azzaroli, F., Giannini, E. G., Rapaccini, G. L., Brunetto, M. R., Masotto, A., Nardone, G., Di Marco, M., Magalotti, D., Trevisani, F., Biselli, M., Caraceni, P., Gramenzi, A., Tovoli, F., Muratori, L., Benevento, F., Allegrini, G., Camma, C., Celsa, C., Giuffrida, P., Stornello, C., Grova, M., Giacchetto, C. M., Rancatore, G., Grassini, M. V., Adotti, V., Gitto, S., Marra, F., Rosi, M., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Dall'Aglio, A. C., Ercolani, G., Mirici, F., de Matthaeis, N., Ponziani, F. R., Missale, G., Olivani, A., Guarino, M., Cossiga, V., Capasso, M., Cela, E. M., Facciorusso, A., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Dell'Isola, S., Franze, M. S., Saitta, C., Sauchella, A., Dajti, E., Ravaioli, F., Pieri, G., Torres, M. C. P., Oliveri, F., Ricco, G., Romagnoli, V., Inno, A., Marchetti, F., Coccoli, P., Malerba, A., Cappelli, A., Golfieri, R., Mosconi, C., Matteo, Renzulli, Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Rampoldi, Davide, Lani, Lorenzo, Granito, Alessandro, Sangiovanni, Angelo, Cabibbo, Giuseppe, Farinati, Fabio, Campani, Claudia, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Raimondo, Giovanni, Gasbarrini, Antonio, Mega, Andrea, Biasini, Elisabetta, Sacco, Rodolfo, Morisco, Filomena, Caturelli, Eugenio, Vidili, Gianpaolo, Azzaroli, Francesco, Giannini, Edoardo G, Rapaccini, Gian Ludovico, Brunetto, Maurizia Rossana, Masotto, Alberto, Nardone, Gerardo, Di Marco, Mariella, Magalotti, Donatella, and Trevisani, Franco

Subjects
Atezolizumab-bevacizumab, Clinical Trials as Topic, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Hepatocellular, Systemic therapy, Hepatology, Hepatocellular carcinoma, Tirosin-kinase inhibitor, Liver Neoplasms, Gastroenterology, Bevacizumab, Feasibility Studie, Tyrosine, Human
Abstract

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (29%) patients were qualified for atezolizumab-bevacizumab therapy. The main exclusion causes were Child-Pugh class and Performance Status. Adopting the more permissive inclusion criteria of SHARP trial, 535 patients became eligible. The median overall survival of tyrosine-kinase inhibitors patients was 14.9 months, longer in eligible patients than in their counterpart due to better baseline liver function and oncological features.Conclusion: Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the reg-istration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients.(c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Published
2022
Full Text
View/download PDF

13. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence

Author

Concetta Pitrone, Vito Di Marco, Gabriele Rancatore, Ciro Celsa, Paolo Giuffrida, Caterina Stornello, Calogero Cammà, Giuseppe Cabibbo, Carmelo Marco Giacchetto, Mauro Grova, Celsa, C., Stornello, C., Giuffrida, P., Giacchetto, C.M., Grova, M., Rancatore, G., Pitrone, C., Di Marco, V., Camma', C., and Cabibbo, G.

Subjects
Oncology, medicine.medical_specialty, Carcinoma, Hepatocellular, Sustained Virologic Response, Survival, Hepatocellular carcinoma, Hepatitis C virus, Specialties of internal medicine, Disease, Direct-acting antivirals, Direct-acting antiviral, medicine.disease_cause, Chronic liver disease, Antiviral Agents, Recurrence, Internal medicine, Carcinoma, Humans, Medicine, Adverse effect, Retrospective Studies, Hepatology, business.industry, Liver Neoplasms, General Medicine, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Residual risk, RC581-951, Observational study, Hepatitis C viru, business
Abstract

Direct-acting antivirals (DAAs) revolutionized the treatment of chronic HCV-related disease achieving high rates of sustained virological response (SVR), even in advanced cirrhosis, with modest contraindications and a low rate of adverse events. However, the risk of hepatocellular carcinoma (HCC) persists due to the underlying chronic liver disease, both in patients with and without history of HCC. Although some initial studies reported a presumptive high risk of HCC development after DAA therapy, more recent observational studies denied this hypothesis. The residual risk for HCC occurrence after HCV eradication seems being progressively reduced with time after SVR. Data on recurrence of HCC after DAA exposure in patients with previously treated carcinoma initially reported conflicting results too, this being also due to methodological issues in analysis of retrospective multicenter studies. Anyway, current evidence support the use of DAAs in HCV-HCC treated patients, without any higher risk of tumor recurrence linked to antiviral therapy. Less effort has been made to evaluate the efficacy of DAA therapy in patients with untreated active HCC and it has been questioned whether a lower rate of SVR would be obtained among patients with active HCC. Studies conducted in this perspective concluded that HCC status does not influence the likelihood to obtain SVR with DAAs, making DAAs appropriate in HCC-active patients. As far as survival is concerned, recent studies conducted in cirrhotic HCV-related early-stage HCC found that DAAs improved overall survival, a benefit probably due to the reduction of hepatic decompensation.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results